NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet which is used for prescribing and managing clinicians for programming implanted devices and managing patient care; and patient data management system, a secure online database that collects data that have been recorded by the RNS System; and nSight Platform, which provide clinicians with personalized patient reports, as well as programming suggestions. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
Frequently asked questions
What sector does Neuropace Inc (NPCE) operate in?
Neuropace Inc belongs to the Healthcare sector and operates in the Medical Devices industry.
What is Neuropace Inc (NPCE) current stock price?
As of the latest data, Neuropace Inc stock price is $14.77, with a previous close of $14.51. Neuropace Inc gained $0.26 in the last trading session, representing a 1.79% increase.
What is Neuropace Inc (NPCE) current market capitalization?
Neuropace Inc market cap is approximately 506.97 million.
What is Neuropace Inc (NPCE) Earnings Per Share (EPS)?
The trailing EPS is -$0.47, and the forward EPS is -$0.26.
What is Neuropace Inc (NPCE) EBITDA?
Neuropace Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -4.56 million.
Does Neuropace Inc (NPCE) pay dividends?
No. Neuropace Inc does not pay a dividend.
How did Neuropace Inc (NPCE) perform in its most recent earnings report?
In the last report (June 30, 2026), Neuropace Inc posted an EPS surprise of 5.26% and a revenue surprise of 0.74%.
What is Neuropace Inc (NPCE) beta (volatility) score?
Neuropace Inc has a beta of 1.937, suggesting it is more volatile than the market.
